On Risk Factors and Genetic Cancer Risk Assessment
Daly MB, Axilbund JE, Buys S: Genetic/familial high-risk assessment: Breast and ovarian. J Natl Compr Canc Netw 8:562-594, 2010.
Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250-1256, 2009.
Ravdin PM, Cronin KA, Howlader N, et al: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674, 2007.
Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87, 2009.
Robson ME, Storm CD, Weitzel J, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893-901, 2010.
Walsh T, Casadei S, Coats KH, et al: Spectrum of mutations in BRCA1 , BRCA2 , CHEK2, and T P53 in families at high risk of breast cancer. JAMA 295:1379-1388, 2006.
Weitzel JN, Blazer KR, Macdonald DJ, et al: Genetics, genomics and cancer risk assessment: State of the art and future directions in the era of personalized medicine. CA Cancer J Clin 61:327-359, 2011.
On Screening and Diagnosis
Baker JA, Lo J: Breast tomosynthesis: State-of-the art and review of the literature. Acad Radiol 18:1298-1310, 2010.
Feigin KN, Keating DM, Telford PM, et al: Clinical breast examination in a comprehensive breast cancer screening program: Contribution and cost. Radiology 240:650-655, 2006.
Hollingsworth AB, Stough RG: Breast MRI screening for high risk patients. Semin Breast Dis 11:67-75, 2008.
Kopans DB: The recent US Preventive Services Task Force Guidelines are not supported by the scientific evidence and should be rescinded. J Am Coll Radiol 7:260-264, 2010.
Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89, 2007.
Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010.
Goss PE, Ingle JN, Alés-Martínez JE, et al: Exemestane(Drug information on exemestane) for breast cancer prevention in postmenopausal women. N Engl J Med 364:2381-2391, 2011.
Prentice RL, Caan B, Chlebowski RT, et al: Low-fat dietary pattern and risk of invasive breast cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295:629-642, 2006.
Vogel VG, Costantino JP, Wickerham DL, et al: National Surgical Adjuvant Breast and Bowel Project (NSABP): Effects of tamoxifen(Drug information on tamoxifen) vs raloxifene(Drug information on raloxifene) on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006.
Weitzel JN, Buys SS, Sherman WH, et al: Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 13:654-658, 2007.
Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone(Drug information on progesterone) receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010.
Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007.